One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

Lorcan McGarvey, Dennis Niewoehner, Sheldon Magder, Paul Sachs, Kay Tetzlaff, Alan Hamilton, Lawrence Korducki, Ulrich Bothner, Claus Vogelmeier, Andrea Koch, Gary T. Ferguson

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


The novel long-acting β2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies. This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a large cohort of patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease 2-4) chronic obstructive pulmonary disease (COPD). The studies compared olodaterol (5 or 10 g) QD via Respimat®, formoterol 12 g twice daily (BID) via Aerolizer® (1222.13 and 1222.14), and placebo for 48 weeks. Patients continued receiving background maintenance therapy, with ∼60% receiving concomitant cardiovascular therapy and 25% having a history of concomitant cardiac disease. Pre-specified analyses of pooled data assessed the adverse events (AEs) and serious AEs in the whole population, and in subgroups with cardiac disease, along with in-depth electrocardiogram and Holter monitoring. In total, 3104 patients were included in the safety analysis: 876 received olodaterol 5 g, 883 received olodaterol 10 g, 885 received placebos, and 460 received formoterol 12 g BID. Overall incidence of on-treatment AEs (71.2%), serious AEs (16.1%), and deaths (1.7%) were balanced across treatment groups. Respiratory and cardiovascular AEs, including major adverse cardiac events, were reported at similar frequencies in placebo and active treatment groups. The safety profiles of both olodaterol 5 g (marketed and registered dose) and 10 g QD delivered via Respimat® are comparable to placebo and formoterol BID in this population, with no safety signals identified.

Original languageEnglish (US)
Pages (from-to)484-493
Number of pages10
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Issue number5
StatePublished - Sep 3 2015

Bibliographical note

Funding Information:
This work was supported by Boehringer Ingelheim Pharma GmbH & Co. KG. Medical writing assistance was provided by Caitlin Watson, PhD, of Complete HealthVizion, which was contracted and compensated by Boehringer Ingelheim Pharma GmbH & Co. KG.

Publisher Copyright:
© 2015 © L. McGarvey, D. Niewoehner, S. Magder, P. Sachs, K. Tetzlaff, A. Hamilton, L. Korducki, U. Bothner, C. Vogelmeier, A. Koch, G. T. Ferguson.


  • Mortality Adjudication Committee
  • bronchodilator
  • cardiac safety
  • long-acting β2-agonist


Dive into the research topics of 'One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis'. Together they form a unique fingerprint.

Cite this